NCT04031885: A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive, HER2 Negative Metastatic Breast Cancer

NCT04031885
Breast Cancer Type: HR+ & HER2-negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 4
Drug Category: Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have had at least 1 line of hormone therapy
Exclusions: Patients with untreated or symptomatic brain metastases; Patients who have had any systemic treatment after their breast cancer has spread unless it is endocrine therapy
https://ClinicalTrials.gov/show/NCT04031885

Comments are closed.

Up ↑